- Draig bags another $65M to speed testing of brain drugsThe cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder.BioPharma Dive · 14d ago↗ source
- Biogen's tau drug reports mixed Alzheimer's results, as low dose performs betterLONDON — Biogen's attempt to treat Alzheimer's by going after a protein that forms toxic tangles in the brain showed some of the strongest proof yet that it could slow dementia. But the results wer…Endpoints · 14d ago↗ source
- Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugsThe study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.